Mirae Asset Global ETFs Holdings’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-29,288
Closed -$963K 3314
2026
Q1
$963K Buy
29,288
+2,045
+8% +$80.2K ﹤0.01% 1537
2025
Q4
$1.26M Buy
27,243
+3,112
+13% +$171K ﹤0.01% 1392
2025
Q3
$1.63M Buy
+24,131
New +$1.79M ﹤0.01% 1236
2025
Q2
Sell
-17,360
Closed -$1.24M 3215
2025
Q1
$1.24M Buy
17,360
+189
+1% +$9.2K ﹤0.01% 1387
2024
Q4
$773K Buy
17,171
+2,278
+15% +$118K ﹤0.01% 1689
2024
Q3
$749K Buy
14,893
+12,862
+633% +$616K ﹤0.01% 1713
2024
Q2
$84.8K Buy
+2,031
New +$86.1K ﹤0.01% 2629

Mirae Asset Global ETFs Holdings's SLNO Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 29,288 shares — an estimated $963K sold.

Mirae Asset Global ETFs Holdings first reported a position in SLNO in Q2 2024 and held it in 7 quarters. The position peaked at $1.63M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Mirae Asset Global ETFs Holdings reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 29,288 Soleno Therapeutics shares in Q2 2026, an estimated $963K.
  • Mirae Asset Global ETFs Holdings first reported a position in Soleno Therapeutics in Q2 2024 and held it in 7 quarters.
  • Mirae Asset Global ETFs Holdings's Soleno Therapeutics position peaked at $1.63M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.